Interleukin 17 inhibitors (Ixekizumab, Secukinumab, Brodalumab) are used successfully in the biological treatment of psoriasis, PA, AS, RA, but at the same time mediate the immune response against bacteria and fungi [3]. The gene discussed is IL17A; the disease is psoriasis.